Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Short Interest Up 19.2% in December

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) saw a large increase in short interest in the month of December. As of December 31st, there was short interest totaling 11,178,279 shares, an increase of 19.2% from the December 15th total of 9,374,807 shares. Currently, 11.6% of the shares of the stock are sold short. Based on an average trading volume of 2,469,542 shares, the short-interest ratio is presently 4.5 days. Based on an average trading volume of 2,469,542 shares, the short-interest ratio is presently 4.5 days. Currently, 11.6% of the shares of the stock are sold short.

Insider Activity at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Adam Dubow sold 4,319 shares of the stock in a transaction on Monday, November 17th. The stock was sold at an average price of $8.91, for a total transaction of $38,482.29. Following the completion of the transaction, the insider directly owned 62,626 shares of the company’s stock, valued at approximately $557,997.66. This trade represents a 6.45% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Charles N. York II sold 4,062 shares of the business’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $8.91, for a total value of $36,192.42. Following the completion of the sale, the chief financial officer directly owned 294,715 shares in the company, valued at $2,625,910.65. This represents a 1.36% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 28,001 shares of company stock valued at $249,489. Insiders own 6.20% of the company’s stock.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Institutional investors have recently bought and sold shares of the business. Deerfield Management Company L.P. grew its stake in shares of Day One Biopharmaceuticals by 26.4% in the 3rd quarter. Deerfield Management Company L.P. now owns 4,705,413 shares of the company’s stock valued at $33,173,000 after buying an additional 982,282 shares in the last quarter. Franklin Resources Inc. lifted its stake in Day One Biopharmaceuticals by 2.0% in the second quarter. Franklin Resources Inc. now owns 4,097,625 shares of the company’s stock valued at $26,635,000 after acquiring an additional 79,255 shares during the last quarter. Rubric Capital Management LP bought a new stake in Day One Biopharmaceuticals in the third quarter worth approximately $23,808,000. Vestal Point Capital LP increased its stake in shares of Day One Biopharmaceuticals by 15.5% during the 2nd quarter. Vestal Point Capital LP now owns 3,000,000 shares of the company’s stock worth $19,500,000 after purchasing an additional 401,873 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Day One Biopharmaceuticals by 11.2% during the 2nd quarter. Geode Capital Management LLC now owns 1,712,429 shares of the company’s stock valued at $11,132,000 after purchasing an additional 171,964 shares in the last quarter. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Day One Biopharmaceuticals Stock Down 3.2%

Shares of DAWN stock traded down $0.34 during trading hours on Monday, reaching $10.16. 4,168,538 shares of the stock traded hands, compared to its average volume of 2,026,168. The firm has a market capitalization of $1.04 billion, a PE ratio of -6.68 and a beta of -1.27. Day One Biopharmaceuticals has a 1-year low of $5.64 and a 1-year high of $13.53. The business has a fifty day moving average price of $9.16 and a 200 day moving average price of $7.82.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.09. The firm had revenue of $39.80 million for the quarter, compared to analysts’ expectations of $38.20 million. Day One Biopharmaceuticals had a negative net margin of 113.53% and a negative return on equity of 32.05%. The company’s quarterly revenue was down 57.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.38 EPS. Research analysts expect that Day One Biopharmaceuticals will post -0.72 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Needham & Company LLC reissued a “buy” rating and issued a $16.00 price target on shares of Day One Biopharmaceuticals in a report on Monday, November 24th. TD Cowen assumed coverage on shares of Day One Biopharmaceuticals in a report on Tuesday, January 13th. They set a “buy” rating and a $34.00 target price for the company. HC Wainwright restated a “buy” rating and issued a $25.00 price target on shares of Day One Biopharmaceuticals in a research report on Monday, November 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a research report on Monday, December 29th. Finally, Zacks Research raised Day One Biopharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 13th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.71.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.